ArticleBMJ open2023

Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial.

Mao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.